Free Publications

Search for cll returned 217 results

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.

Transcript

Hello, everyone, and welcome to NHL and CLL–Diagnosis and Treatment Update, a free telephone web education program. It is my pleasure to introduce your moderator Lauren Berger of The Leukemia & Lymphoma Society.

  • PDF
Read more

Strengthening the Quality of CLL Care Among Clinical Teams and Health Systems

November 30, 2017

In collaboration with PRIME®
  Click Here to Participate CE Credit Available Until: 11/29/18 1 AMA PRA Category 1 CreditTM/1 ACPE credit for pharmacists/ 1 CE contact hour for nurses and case managers

  Learning Objectives Upon completion of this activity, participants will be able to: Assess common gaps in guideline-directed, coordinated, and patient-centered care for patients with CLL Evaluate the ap ...

  • Photo
Read more

Real-World Patient Experiences & Evidence-based Treatment Strategies in CLL/SLL and FL

Real-World Patient Experiences & Evidence-based Treatment Strategies in CLL/SLL and FL In collaboration with PRIME®
  Click Here to Participate   CE Credit Available Until: October 16, 2019 1.0 AMA PRA Category 1 CreditTM/1.0 ACPE credit for pharmacists/1.0 AAPA Category I CME credit for physician assistants/ 1.0 AANP credit for nurse practitioners/1.0 CE contact hour for nurses, case managers and certified health education specialists
Targe ...

  • Photo
Read more

Managing Toxicities of Novel Therapies and Coordinating Care for CLL/SLL and FL Patients

Managing Toxicities of Novel Therapies and Coordinating Care for CLL/SLL and FL Patients In collaboration with PRIME®
  Click Here to Participate CE Credit Available Until: October 16, 2019 1.0 AMA PRA Category 1 CreditTM/1.0 ACPE credit for pharmacists/1.0 AAPA Category I CME credit for physician assistants/ 1.0 AANP credit for nurse practitioners/1.0 CE contact hour for nurses, case managers and certified health education specialists
  Target Au ...

  • Photo
Read more

Pages

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.